Sep 10, 2020, 06:54 AM by Michael Croft

CAMBRIDGE, UNITED KINGDOM - Sep 9, 2020 - Optibrium™, leading providers of software and services for drug discovery, today announced a peer-reviewed publication, ‘Practical Applications of Deep Learning to Impute Heterogeneous Drug Discovery Data’, in the Journal of Chemical Information and Modeling [1]

Sep 10, 2020, 06:49 AM by Michael Croft

BISHOP'S STORTFORD, UNITED KINGDOM - Sep 9, 2020 - Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced the introduction of eln

Sep 9, 2020, 14:39 PM by Michael Croft

NEW YORK, NY - Sep 9, 2020 - Phosplatin Therapeutics, a clinical stage pharmaceutical company focused on oncology therapeutics, today announced the addition to its growing team of Joseph F

Sep 9, 2020, 13:27 PM by Michael Croft

BAR HARBOR, ME, UNITED STATES - Sep 9, 2020 - Scientists have long known that chronic stress experienced early in life, or even chronic prenatal exposure to maternal stress hormones in the womb, can shorten lifespan and contribute to age-related chronic diseases like arthritis, asthma, cancer, cardiovascular disease, diabetes, heart disease and even mental illness later in life -- long after the source of stress has been removed

Sep 9, 2020, 09:46 AM by Michael Croft

LOUVAIN-LA-NEUVE, BELGIUM - Sep 9, 2020 - European Centre for Clinical Research Training (ECCRT)  has been selected as a premium provider for continuous online learning by IDDI, a BIOSTATISTICAL AND ECLINICAL SERVICES provider for Pharmaceutical and Biotechnology companies

Sep 9, 2020, 07:20 AM by Michael Croft

Bio-IT World | At the Drug Discovery Chemistry Virtual conference, researchers from industry and academia provide a glimpse into the expanse of pharmaceuticals available beyond Lipinski’s Rule of 5, an endeavor that will hopefully enable the development of much more specific agents with vastly expanded targetable options.

Sep 8, 2020, 15:11 PM by Michael Croft

LONDON, UK - Sep 8, 2020 - Lifebit Biotech announced today the appointment of Frank Seo, who joins the company as General Manager

Sep 8, 2020, 13:10 PM by Michael Croft

Bio-IT World  A newly developed translatable components regression (TransComp-R) model, developed by researchers from Purdue University and the Massachusetts Institute of Technology (MIT), recently identified an overlooked biological mechanism possibly responsible for resistance to the drug infliximab commonly prescribed to patients with inflammatory bowel disease (IBD).

Sep 8, 2020, 04:57 AM by Michael Croft

SALUGGIA, ITALY AND HAIFA, ISRAEL - Sep 8, 2020 -   DiaSorin (FTSE MIB: DIA) and MeMed have announced today the creation of a strategic partnership to accelerate the deployment of a novel, host-protein signature-based assay

Sep 7, 2020, 02:06 AM by Michael Croft

SHIRLEY, NY, UNITED STATES - Sep 9, 2020 - Chelating agents are chemical compounds that react with metal ions to form a stable, water-soluble complex

Sep 6, 2020, 23:56 PM by Michael Croft

SHIRLEY, NY, UNITED STATES - Sep 7, 2020 - Chimeric antigen receptor (CAR) T cell therapy represents the culmination of research in both immunology and oncology fields

Sep 4, 2020, 04:25 AM by Michael Croft

Bio-IT World   A potential new screening approach, improving immune response to vaccines, new mouse models of SARS-CoV-2, exploring ACE2 receptor activity, a protein that may trigger blood clots, the importance of placenta tissue, hopeful signs that a single vaccine can do the job, and a bioengineering technique to boost production of proteins that prompt antibody development. Plus, machine learning to help identify drug combinations that can be repurposed as potential therapies.

Sep 3, 2020, 16:15 PM by Michael Croft

BOSTON, MA - Sep 3, 2020 - Biofourmis, a fast-growing global leader in digital therapeutics that powers personalized predictive care, has announced the completion of a $100 million Series C financing round led by SoftBank Vision Fund 2,[1] with participation by existing investors Openspace Ventures, MassMutual Ventures, Sequoia Capital and EDBI

Sep 3, 2020, 07:54 AM by Michael Croft

AMSTERDAM, THE NETHERLANDS - Sep 3, 2020 - : CPhI Festival of Pharma (5-16 October, 2020), the world’s largest ever virtual pharma expo, unveils its ground-breaking two-week long agenda

Sep 3, 2020, 01:10 AM by Michael Croft

Bio-IT World | Phil Baran of Scripps Research is dedicated to simplifying chemical synthesis, not to create techniques that are “gimmicky” but will instead become the standard processes of the future. Maybe, “fifty years from now,” he predicts, “we’ll look back in curiosity at chemists of our age who had stages in their syntheses instead of making everything in 1-3 steps.”

Sep 2, 2020, 13:30 PM by Michael Croft

Bio-IT World  PrecisionFDA and The Genome in a Bottle (GIAB) consortium have announced the results of the Truth Challenge V2: Calling Variants from Short and Long Reads in Difficult-to-Map Regions such as segmental duplications, and the Major Histocompatibility Complex (MHC).

Sep 2, 2020, 10:53 AM by Michael Croft

LONDON, UNITED KINGDOM - Sep 2, 2020 - Senior team at healthcare agency Page & Page become Partners Significant changes at Page & Page and Partners also include a new London office, a series of client wins and company growth during Covid  London, UKx

Sep 2, 2020, 05:23 AM by Michael Croft

EDINBURGH, UNITED KINGDOM - Sep 2, 2020 - Asklepios BioPharmaceutical, Inc. (AskBio), a leading, clinical-stage gene therapy company dedicated to developing adeno-associated virus (AAV) gene therapies for genetic disorders, announces the award of a £1

Sep 1, 2020, 14:33 PM by Michael Croft

BOYNTON BEACH, FL - Sep 1, 2020 - FamHis, Inc. announces the completion and worldwide release of their next-generation family health history platform FamGenix

Sep 1, 2020, 13:55 PM by Michael Croft

Bio-IT World | The 2020 Bio-IT World Conference & Expo Virtual includes three days full of content, networking, and interaction across 16 tracks, plenary session, workshops, posters, awards, and happy hours. And for the first time ever, many presentations will be available on demand after their first showing. We are already building our agenda.